As of Wednesday close, Sorrento Therapeutics Inc.’s (NASDAQ:SRNE) stock traded at $1.38. The average number of shares traded per day over the past five days has been 6,635,860 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.1400 fall in that time frame. In the last twenty days, the average volume was 7,650,650, while in the previous 50 days, it was 7,142,414.
Since last month, SRNE stock retreated -13.21%. Shares of the company fell to $1.3500 on 11/23/22, the lowest level in the past month. A 52-week high of $6.53 was reached on 01/04/22 after having rallying from a 52-week low of $1.15. Since the beginning of this year, SRNE’s stock price has dropped by -70.32% or -$3.2700, and marked a new high 2 times. However, the stock has declined by -78.87% since its 52-week high.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
SRNE stock investors should be aware that Sorrento Therapeutics Inc. (SRNE) stock had its last reported insider trading activity 79 days ago on Sep 07. Ji Henry, the of the company, purchased of 88,888 shares for $2.02 on Sep 07. It resulted in a $179,349 investment by the insider. Ji Henry added 55,555 shares at an average price of $1.96 on Sep 06. The insider now owns 4,676,917 shares following the transaction. On Aug 26, Ji Henry bought 33,333 shares at $2.11 apiece. The transaction was valued at $70,333.
The stock’s beta is 2.19. Besides these, the trailing price-to-sales (P/S) ratio of 10.80, the price-to-book (PB) ratio of 4.76.
In the three months ended June 29, Sorrento Therapeutics Inc.’s quick ratio stood at 0.80, while its current ratio was 0.90, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.14, and the total debt-to-equity ratio was 0.54. On the profitability front, the trailing twelve-month gross margin is 62.10% percent. Based on annual data, SRNE earned $39.87 million in gross profit and brought in $52.9 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -169.30%. Return on equity (ROE) for the past 12 months was -346.90%.
In Sorrento Therapeutics Inc.’s quarter-end financial report for June 29, it reported total debt of $17.8 million against cash and short-term investments of $47.18 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. SRNE’s revenue rose 30.69% to $11.46 million during the quarter, while net income inched up to $17.4 million. While analysts expected Sorrento Therapeutics Inc. to report -$0.25 quarterly earnings, the actual figure was -$0.54 per share, beating the consensus estimate by -116.00%. During the quarter, the company generated -$15.3 million in EBITDA. The liabilities of Sorrento Therapeutics Inc. were 485.41 million at the end of its most recent quarter ended June 29, and its total debt was $204.61 million. The value of shareholders’ equity is $471.88 million.
This quick technical analysis looks at Sorrento Therapeutics Inc.’s (SRNE) price momentum. With a historical volatility rate of 88.44%, the RSI 9-day stood at 37.95% on 23 November.
With respect to its five-day moving average, the current Sorrento Therapeutics Inc. price is down by -9.21% percent or -$0.1400. At present, SRNE shares trade -13.21% below its 20-day simple moving average and -46.09% percent below its 100-day simple moving average. However, the stock is currently trading approximately -33.33% below its SMA50 and -57.93% below its SMA200.
Stochastic coefficient K was 5.66% and Stochastic coefficient D was 7.08%, while ATR was 0.1272. Given the Stochastic reading of 5.56% for the 14-day period, the RSI (14) reading has been calculated as 41.45%. As of today, the MACD Oscillator reading stands at -0.1378, while the 14-day reading stands at -0.1214.
Cantor Fitzgerald launched its rating on Sorrento Therapeutics Inc. (NASDAQ: SRNE) to an Overweight in a note to investors on November 02, 2022. Sorrento Therapeutics Inc. (SRNE) has been rated Buy by analysts. According to 0 brokerage firms, SRNE is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Sorrento Therapeutics Inc. stock as buy, with 2 recommending it as overweight.
With a median target price of $5.00, the current consensus forecast for the stock is $5.00 – $5.00. Based on these forecasts, analysts predict Sorrento Therapeutics Inc. (SRNE) will achieve an average price target of $5.00.